General Information of Drug (ID: DMVUX1C)

Drug Name
BFH-772 Drug Info
Synonyms NVP-BFH-772
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Phase 2 [1]
Cross-matching ID
PubChem CID
24756034
CAS Number
CAS 890128-81-1
TTD Drug ID
DMVUX1C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [3]
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [4]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [4]
KH-902 DM8VO16 Diabetic macular edema 9B71.02 Phase 3 [5]
ABP 938 DM00ACQ Neovascular age-related macular degeneration 9B78.3Z Phase 3 [6]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
BAY-57-9352 DMVA5NS Gastric adenocarcinoma 2B72 Phase 2 [8]
X-82 DMW1NKO Age-related macular degeneration 9B75.0 Phase 2 [4]
Vorolanib DMIM1U9 Non-small-cell lung cancer 2C25 Phase 2 [9]
ASP-8477 DMBZQS7 Neuropathic pain 8E43.0 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor receptor (VEGFR) TTVJ1D8 NOUNIPROTAC Agonist [2]

References

1 ClinicalTrials.gov (NCT01449591) Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients. U.S. National Institutes of Health.
2 CA patent application no. 841416, Method of selecting therapeutic indications.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
6 Clinical pipeline report, company report or official report of Amgen
7 National Cancer Institute Drug Dictionary (drug id 452042).
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
10 ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.